• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

    9.410 +2.480 (+35.79%)
    Streaming Delayed Price Updated: 9:51 AM EDT, Aug 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 18,551,963
    Open 8.760
    Bid (Size) 9.400 (600)
    Ask (Size) 9.420 (200)
    Prev. Close 6.930
    Today's Range 8.400 - 9.755
    52wk Range 2.745 - 8.440
    Shares Outstanding 287,686,199
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    AI Found an Influenza Target That Survives Viral Mutation
    Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT) 
    From Equity Insider
    Via GlobeNewswire
    News headline image
    AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial ↗
    AbCellera Biologics (NASDAQ:ABCL) reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot... 
    Via MarketBeat

    Performance

    YTD
    +174.3%
    +174.3%
    1 Month
    +38.4%
    +38.4%
    3 Month
    +79.2%
    +79.2%
    6 Month
    +192.2%
    +192.2%
    1 Year
    +109.1%
    +109.1%

    More News

    Read More
    News headline image
    AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile
    From AbCellera Biologics Inc.
    Via Business Wire
    AbCellera Biologics (NASDAQ:ABCL) Misses Q2 Estimates, Falls Short on Revenue and EPS ↗
    Via Chartmill
    AbCellera Biologics Inc (NASDAQ:ABCL) Reports Narrower-Than-Expected Loss on Patent Settlement Windfall ↗
    Via Chartmill
    Topics Intellectual Property
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    Get insights into the top gainers and losers of Friday's after-hours session. ↗
    Via Chartmill
    News headline image
    AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera Biologics Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    AbCellera Reports Q2 2026 Business Results
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera Appoints Dr. Lynn Seely to its Board of Directors
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera Appoints Dr. Victor Sandor to its Board of Directors
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam ↗
    Via MarketBeat
    News headline image
    AbCellera Biologics Q1 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    AbCellera (ABCL) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Topics Intellectual Property
    Stay updated with the stocks that are on the move in today's after-hours session. ↗
    Via Chartmill
    News headline image
    AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Present at Upcoming Investor Conferences in May and June 2026
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    CRA: Here’s the TFSA Contribution Room for 2026 and Why Now Is the Best Time to Use It ↗
    Via The Motley Fool
    These stocks are moving in today's after hours session ↗
    Via Chartmill

    Frequently Asked Questions

    Is AbCellera Biologics Inc. - Common Shares publicly traded?
    Yes, AbCellera Biologics Inc. - Common Shares is publicly traded.
    What exchange does AbCellera Biologics Inc. - Common Shares trade on?
    AbCellera Biologics Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for AbCellera Biologics Inc. - Common Shares?
    The ticker symbol for AbCellera Biologics Inc. - Common Shares is ABCL on the Nasdaq Stock Market
    What is the current price of AbCellera Biologics Inc. - Common Shares?
    The current price of AbCellera Biologics Inc. - Common Shares is 9.410
    When was AbCellera Biologics Inc. - Common Shares last traded?
    The last trade of AbCellera Biologics Inc. - Common Shares was at 08/10/26 09:51 AM ET
    What is the market capitalization of AbCellera Biologics Inc. - Common Shares?
    The market capitalization of AbCellera Biologics Inc. - Common Shares is 2.71B
    How many shares of AbCellera Biologics Inc. - Common Shares are outstanding?
    AbCellera Biologics Inc. - Common Shares has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.